314 related articles for article (PubMed ID: 22258336)
1. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
Shibata H; Itoh H
Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor activation in obesity hypertension.
Nagase M; Fujita T
Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
5. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
Morimoto S; Ichihara A
Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
[TBL] [Abstract][Full Text] [Related]
6. [Aldosterone].
Tanabe A; Tsuiki M; Watanabe D; Takagi S; Takano K; Naruse M
Rinsho Byori; 2004 Aug; 52(8):704-10. PubMed ID: 15478626
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Steele JL; Henik RA; Stepien RL
Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
[TBL] [Abstract][Full Text] [Related]
8. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
Kawarazaki W; Fujita T
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
[TBL] [Abstract][Full Text] [Related]
10. RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients.
Semplicini A; Strapazzon G; Papparella I; Sartori M; Realdi A; Macchini L; Calò LA; Ceolotto G
J Hypertens; 2010 May; 28(5):1104-8. PubMed ID: 20375904
[TBL] [Abstract][Full Text] [Related]
11. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
13. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
[TBL] [Abstract][Full Text] [Related]
15. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone as a cardiovascular risk factor.
Rossi G; Boscaro M; Ronconi V; Funder JW
Trends Endocrinol Metab; 2005 Apr; 16(3):104-7. PubMed ID: 15808807
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone and refractory hypertension: a prospective cohort study.
Sartori M; Calò LA; Mascagna V; Realdi A; Macchini L; Ciccariello L; De Toni R; Cattelan F; Pessina AC; Semplicini A
Am J Hypertens; 2006 Apr; 19(4):373-9; discussion 380. PubMed ID: 16580572
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone and end-organ damage.
Marney AM; Brown NJ
Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
Funder JW
Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
